NYSE:BAXBaxter International Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Baxter International Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $88.65 -1.83 (-2.02 %) (As of 06/4/2020 02:22 PM ET) Add Compare Share Today's Range$88.39Now: $88.65▼$90.0550-Day Range$85.51MA: $88.97▼$94.1452-Week Range$69.10Now: $88.65▼$95.19Volume883,935 shsAverage Volume2.69 million shsMarket Capitalization$44.96 billionP/E Ratio26.78Dividend Yield0.97%Beta0.83 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingBaxter International has received a consensus rating of Buy. The company's average rating score is 2.74, and is based on 14 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $96.42, Baxter International has a potential upside of 9.0% from its current price of $88.42.Amount of Analyst CoverageBaxter International has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesBaxter International has received 679 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBaxter International has received 591 “underperform” votes. (Add your “underperform” vote.)Community SentimentBaxter International has received 53.46% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote “Outperform” if you believe BAX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BAX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 3.3 Dividend Strength Dividend LeadershipBaxter International is a leading dividend payer. It pays a dividend yield of 0.97%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBaxter International has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Baxter International is 26.59 %. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Baxter International will have a dividend payout ratio of 22.92 % next year. This indicates that Baxter International will be able to sustain or increase its dividend. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Baxter International insiders have sold 489.03% more of their company's stock than they have bought. Specifically, they have bought $803,818.00 in company stock and sold $4,734,752.00 in company stock.Percentage Held by InsidersOnly 0.13% of the stock of Baxter International is held by insiders.Percentage Held by Institutions83.72% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Baxter International are expected to grow by 16.72% in the coming year, from $3.29 to $3.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Baxter International is 26.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.28.Price to Earnings Ratio vs. SectorThe P/E ratio of Baxter International is 26.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.63.Price to Earnings Growth RatioBaxter International has a PEG Ratio of 2.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBaxter International has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:BAX Previous Symbol CUSIP07181310 CIK10456 Webwww.baxter.com Phone224-948-2000Debt Debt-to-Equity Ratio0.84 Current Ratio2.74 Quick Ratio2.19Price-To-Earnings Trailing P/E Ratio26.78 Forward P/E Ratio26.95 P/E Growth2.51 Sales & Book Value Annual Sales$11.36 billion Price / Sales3.96 Cash Flow$4.84 per share Price / Cash Flow18.31 Book Value$15.50 per share Price / Book5.72Profitability EPS (Most Recent Fiscal Year)$3.31 Net Income$1.00 billion Net Margins8.85% Return on Equity22.70% Return on Assets9.79%Miscellaneous Employees50,000 Outstanding Shares507,210,000Market Cap$44.96 billion Next Earnings Date7/23/2020 (Estimated) OptionableOptionable BAX Rates by TradingView Receive BAX News and Ratings via Email Sign-up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter. Baxter International (NYSE:BAX) Frequently Asked Questions How has Baxter International's stock been impacted by COVID-19 (Coronavirus)? Baxter International's stock was trading at $77.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BAX shares have increased by 13.4% and is now trading at $88.42. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Baxter International? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International. When is Baxter International's next earnings date? Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Baxter International. How were Baxter International's earnings last quarter? Baxter International Inc (NYSE:BAX) released its quarterly earnings results on Thursday, April, 30th. The medical instruments supplier reported $0.82 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.73 by $0.09. The medical instruments supplier earned $2.80 billion during the quarter, compared to analysts' expectations of $2.74 billion. Baxter International had a net margin of 8.85% and a return on equity of 22.70%. Baxter International's revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.76 EPS. View Baxter International's earnings history. How often does Baxter International pay dividends? What is the dividend yield for Baxter International? Baxter International announced a quarterly dividend on Tuesday, May 5th. Stockholders of record on Friday, June 5th will be given a dividend of $0.245 per share on Wednesday, July 1st. This represents a $0.98 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date of this dividend is Thursday, June 4th. This is a boost from Baxter International's previous quarterly dividend of $0.22. View Baxter International's dividend history. How will Baxter International's stock buyback program work? Baxter International declared that its Board of Directors has approved a share repurchase plan on Tuesday, November 13th 2018, which allows the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 6.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its shares are undervalued. What guidance has Baxter International issued on next quarter's earnings? Baxter International issued an update on its first quarter earnings guidance on Tuesday, March, 17th. The company provided earnings per share (EPS) guidance of $0.72-0.74 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.81. What price target have analysts set for BAX? 19 Wall Street analysts have issued 12-month price targets for Baxter International's shares. Their forecasts range from $84.00 to $105.00. On average, they anticipate Baxter International's stock price to reach $96.42 in the next twelve months. This suggests a possible upside of 9.0% from the stock's current price. View analysts' price targets for Baxter International. Has Baxter International been receiving favorable news coverage? News headlines about BAX stock have trended somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Baxter International earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutBaxter International. Are investors shorting Baxter International? Baxter International saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 5,570,000 shares, a decline of 14.6% from the April 30th total of 6,520,000 shares. Based on an average daily volume of 3,330,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.1% of the shares of the company are sold short. View Baxter International's Current Options Chain. Who are some of Baxter International's key competitors? Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Masimo (MASI) and Insulet (PODD). View all competitors. What other stocks do shareholders of Baxter International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Honeywell International (HON), Cisco Systems (CSCO), AT&T (T), Pfizer (PFE), BlackRock (BLK), Verizon Communications (VZ), Abbott Laboratories (ABT) and Procter & Gamble (PG). Who are Baxter International's key executives? Baxter International's management team includes the following people: Mr. José E. Almeida, Chairman, Pres & CEO (Age 57)Mr. James K. Saccaro, Exec. VP & CFO (Age 46)Mr. Sean Martin, Sr. VP & Gen. Counsel (Age 56)Mr. Giuseppe Accogli, Sr. VP & Pres of Americas (Age 48)Mr. Scott Pleau, Sr. VP of Operations (Age 53) What is Baxter International's stock symbol? Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX." Who are Baxter International's major shareholders? Baxter International's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.14%), Wellington Management Group LLP (5.90%), State Street Corp (4.63%), Morgan Stanley (3.83%), Third Point LLC (2.28%) and Veritas Asset Management LLP (1.76%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International. Which major investors are selling Baxter International stock? BAX stock was sold by a variety of institutional investors in the last quarter, including Third Point LLC, Wellington Management Group LLP, Eaton Vance Management, First Trust Advisors LP, Mackenzie Financial Corp, Prudential PLC, AQR Capital Management LLC, and Skandinaviska Enskilda Banken AB publ. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, and John D Forsyth. View insider buying and selling activity for Baxter International. Which major investors are buying Baxter International stock? BAX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Capital International Investors, Veritas Asset Management LLP, Morgan Stanley, Bessemer Group Inc., Nuveen Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, and Sumitomo Mitsui Trust Holdings Inc.. View insider buying and selling activity for Baxter International. How do I buy shares of Baxter International? Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Baxter International's stock price today? One share of BAX stock can currently be purchased for approximately $88.42. How big of a company is Baxter International? Baxter International has a market capitalization of $44.85 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe. What is Baxter International's official website? The official website for Baxter International is www.baxter.com. How can I contact Baxter International? Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
